Advanced glycation end products up-regulate gene expression found in diabetic glomerular disease. - Wikidata - awgldk - TriplyDB

Advanced glycation end products up-regulate gene expression found in diabetic glomerular disease.

Advanced glycation end products up-regulate gene expression found in diabetic glomerular disease.

http://www.wikidata.org/entity/Q35788094

about

Advanced glycation endproduct (AGE) receptor 1 is a negative regulator of the inflammatory response to AGE in mesangial cells Orally absorbed reactive glycation products (glycotoxins): an environmental risk factor in diabetic nephropathy Molecular mechanisms of diabetic retinopathy, general preventive strategies, and novel therapeutic targets Diabetic Kidney Disease: Pathophysiology and Therapeutic Targets Development and prevention of advanced diabetic nephropathy in RAGE-overexpressing mice Advanced glycation: an important pathological event in diabetic and age related ocular disease TGF-beta: a crucial component of the pathogenesis of diabetic nephropathy Role of receptor for advanced glycation end-product (RAGE) and the JAK/STAT-signaling pathway in AGE-induced collagen production in NRK-49F cells Epigenetic histone methylation modulates fibrotic gene expression Type IV collagen is transcriptionally regulated by Smad1 under advanced glycation end product (AGE) stimulation.Serum carboxymethyl-lysine, a dominant advanced glycation end product, is associated with chronic kidney disease: the Baltimore longitudinal study of aging.Autocrine and paracrine mechanisms in the early stages of diabetic nephropathy.The key role of the transforming growth factor-beta system in the pathogenesis of diabetic nephropathy.Neurotoxicity of advanced glycation endproducts during focal stroke and neuroprotective effects of aminoguanidine Inflammatory mediators are induced by dietary glycotoxins, a major risk factor for diabetic angiopathy Advanced glycation and the immune system: stimulation, inhibition or both?Effects of SGLT2 inhibition in human kidney proximal tubular cells--renoprotection in diabetic nephropathy?-374 T/A RAGE polymorphism is associated with chronic kidney disease progression in subjects affected by nephrocardiovascular disease.Diabetic vascular dysfunction: links to glucose-induced reductive stress and VEGF.Diabetic kidney disease: impact of puberty.Activation of bone morphogenetic protein 4 signaling leads to glomerulosclerosis that mimics diabetic nephropathy Advanced glycation end-products induce connective tissue growth factor-mediated renal fibrosis predominantly through transforming growth factor beta-independent pathway.Advanced glycation end products and oxidative stress in type 2 diabetes mellitus.Resistance to glomerulosclerosis in B6 mice disappears after menopause.Aminoguanidine prevents age-related arterial stiffening and cardiac hypertrophy Advanced glycation end products induce glomerular sclerosis and albuminuria in normal rats Emerging drugs for diabetic nephropathy.Advanced glycation endproducts promote adhesion molecule (VCAM-1, ICAM-1) expression and atheroma formation in normal rabbits.Effects of extremely low frequency pulsed magnetic fields on diabetic nephropathy in streptozotocin-treated rats.AGEs and glucose levels modulate type I and III procollagen mRNA synthesis in dermal fibroblasts cells culture Advanced glycation end products and their circulating receptors and level of kidney function in older community-dwelling women Carboxymethyl-lysine, an advanced glycation end product, and decline of renal function in older community-dwelling adults Vascular hypertrophy in experimental diabetes. Role of advanced glycation end products.Advanced glycation end products, oxidative stress and diabetic nephropathy.Naturally occurring inhibitors against the formation of advanced glycation end-products.Role of GLP-1 and DPP-4 in diabetic nephropathy and cardiovascular disease.Smoking in diabetic nephropathy: sparks in the fuel tank?Molecular effects of advanced glycation end products on cell signalling pathways, ageing and pathophysiology.Have we reached the limits for the treatment of diabetic nephropathy?TGF-β: the connecting link between nephropathy and fibrosis.

P2860

Q24563997-AB992C6E-D423-4EEB-969D-7E7D77148148 Q24682750-31101E61-EF67-4D21-9D70-62B608FB153E Q27014620-F95288B5-1860-4588-B58D-24D7FF61137E Q28086840-5FDEA036-0A41-4F04-AA2A-5C6B39694A05 Q28344139-CC0974EA-3DEF-4A31-B353-A0D08D61E5C2 Q28365776-E2233317-9200-4591-A607-58D53B40D068 Q28367170-6FBABF36-4344-45A7-BABF-8ED196E45BB9 Q28570142-24EAC0AF-8CD9-4900-9608-D29B126F421E Q28579049-F791AD9A-4DE8-4109-8BE6-02DF351BC51B Q31036740-C1729817-DCA8-474F-8C31-3C4597B0CEDC Q33691339-E66380EB-BC38-407F-A28A-BE27B5B2A28F Q33793187-3ED52167-3194-48E9-811A-1305C32D8150 Q34333423-837832F8-2F51-41E6-9344-4F0A9C2C8AAB Q34374197-97586D8A-3741-4351-AA11-66E5F9E5DC18 Q34388076-016E8B67-547A-4571-AB80-E3658B6A329F Q34570629-6B9F4AA9-2AF9-4888-BD2F-7957D5F56306 Q34579919-0AE560B8-A78F-4C1D-818C-3532577AFE41 Q34672674-DFD0FF7F-3789-4A0B-9E36-3AB23304BC1B Q34733351-8295335B-98F8-42B3-BAAB-199360F1FEDD Q34826667-8F591A78-312C-40CA-B082-0B8C39E2132A Q35011158-F252252A-BA01-44D1-BA06-43C70DC58F3A Q35103591-CEEDA2E7-0311-4721-BF43-8D566F398229 Q35255473-70876046-57E9-4417-B6A5-EF1D7620BB94 Q35749183-EF7EAC07-9DEF-4516-B343-6A48C621DC3C Q35805813-A57991EE-2A55-425C-B538-6749906F5C14 Q35931294-AFF63CAF-1168-4C13-B86A-43596EB351A4 Q36302838-43F93CEE-F9C8-438C-BDED-7F5A8B782F8C Q36437599-DFEE265A-5691-4193-9B12-F6881BC1A690 Q36476215-CDA830EC-58ED-49C4-AE08-FCC973956E2A Q36528881-5BE8D965-31E8-4E9A-A75B-8D28794999F9 Q37088388-114F8A32-8FF2-4DAE-BE4C-6A9C136D24BD Q37088397-BC77526F-3DB9-4880-95CA-E252D7BAA9D5 Q37364608-AD46BAD6-0256-4947-A9F1-187B7D5499A5 Q37780646-86757C39-29E2-4216-B1C1-D19240B1CD01 Q37903708-9F49FD21-7432-4CA6-8C37-C0EB5489F49C Q38042110-D58F0639-2BE9-4BAA-9E8C-725A5B57C583 Q38072702-181DB57C-8B7C-4D32-9D3F-2A4590960A72 Q38108373-BCA24C55-5FDA-4A31-A4FD-799F8FE2D74B Q38189884-BE987A3B-5647-4AAF-92F0-AA27D65EA964 Q38724337-78DE06A7-7225-4B05-AAF4-4F45E5C6A60B

P2860

Advanced glycation end products up-regulate gene expression found in diabetic glomerular disease.

http://www.wikidata.org/entity/Q35788094

description

1994 nî lūn-bûn

@nan

1994年の論文

@ja

1994年論文

@yue

1994年論文

@zh-hant

1994年論文

@zh-hk

1994年論文

@zh-mo

1994年論文

@zh-tw

1994年论文

@wuu

1994年论文

@zh

1994年论文

@zh-cn

name

Advanced glycation end product ...... n diabetic glomerular disease.

@ast

Advanced glycation end product ...... n diabetic glomerular disease.

@en

type

label

Advanced glycation end product ...... n diabetic glomerular disease.

@ast

Advanced glycation end product ...... n diabetic glomerular disease.

@en

prefLabel

Advanced glycation end product ...... n diabetic glomerular disease.

@ast

Advanced glycation end product ...... n diabetic glomerular disease.

@en

P1433

Q35788094-95682D7D-4B17-421A-94DD-C7903F279D53

P1476

Q35788094-FA0DAF31-5FD3-4F75-9947-5F5309B0A980

P2093

Q35788094-0F4D9F8A-1049-4A63-8F6D-BA1008E7A192

Q35788094-69DE0240-BA7E-4C37-A25B-3027C6C49C6B

Q35788094-6EE3306A-7DAB-4B6D-BD85-8B18F5A942FA

Q35788094-801CB672-514F-47A9-8127-3F59CD759E08

Q35788094-AC4737B3-277B-47DF-9009-B1AAE4DAED65

Q35788094-B72FC826-989E-4A47-BF2E-92E9F5DB05D9

P2860

Q35788094-01A32070-F147-450E-A10E-58BA967F788E

Q35788094-054479F8-9FD9-4F16-BA04-8BDE267062F8

Q35788094-096FF8D7-DBBF-41D0-80C2-84C16A120D3F

Q35788094-302AEABF-5BD5-4005-8CDB-BBBFFCB575F6

Q35788094-457AB862-8FCB-4151-B52C-24DEC0DF7260

Q35788094-499AD857-B1AA-4BD8-A903-D4C30DB9E241

Q35788094-545FAEA5-CD10-4887-8EC7-3C1078AD2FDA

Q35788094-649797F3-FD22-468E-BC0E-603C84F07BA7

Q35788094-74FEF240-9B01-40DB-92BE-9285D44E581A

Q35788094-782C41F9-8A9E-4E32-A8A8-05DB4E6CF613

P304

Q35788094-63425005-0716-4AF1-9ABA-AA56DA6DA13B

P31

Q35788094-804FC2F1-E22F-45C5-915A-1AB5C4ECE28B

P356

Q35788094-632ADF27-280E-4CF3-931A-4CB46F5B8F08

P407

Q35788094-774426B1-2084-4A30-9FD6-408839E67AB9

P433

Q35788094-387F3348-6816-4E2E-B528-739433973E07

P478

Q35788094-668ABC22-73D1-462B-AE68-2F982A5A0816

P577

Q35788094-6B78AD0F-CF64-48E0-AACE-06FE1EF18E5C

P5875

Q35788094-78827345-A596-43FA-A082-32FC845B6997

P698

Q35788094-49A4ADB6-E402-435C-B806-291329BE0EB6

P932

Q35788094-0EAE75A0-72CC-4530-96C6-8D9702ACFAF6

P356

PNAS.91.20.9436

P1433

Proceedings of the National Academy of Sciences of the United States of America

P1476

Advanced glycation end product ...... n diabetic glomerular disease.

@en

P2093

C J He

http://www.w3.org/2001/XMLSchema#string

C W Yang

http://www.w3.org/2001/XMLSchema#string

E P Peten

http://www.w3.org/2001/XMLSchema#string

G E Striker

http://www.w3.org/2001/XMLSchema#string

H Vlassara

http://www.w3.org/2001/XMLSchema#string

L J Striker

http://www.w3.org/2001/XMLSchema#string

P2860

Immunohistochemical detection of advanced glycosylation end products in diabetic tissues using monoclonal antibody to pyrraline

Mechanistic studies of advanced glycosylation end product inhibition by aminoguanidine

Advanced protein glycosylation induces transendothelial human monocyte chemotaxis and secretion of platelet-derived growth factor: role in vascular disease of diabetes and aging.

Advanced glycosylation end products in tissue and the biochemical basis of diabetic complications.

Aminoguanidine prevents diabetes-induced arterial wall protein cross-linking.

Human and rat mesangial cell receptors for glucose-modified proteins: potential role in kidney tissue remodelling and diabetic nephropathy.

Retardation by aminoguanidine of development of albuminuria, mesangial expansion, and tissue fluorescence in streptozocin-induced diabetic rat.

Receptor-mediated interactions of advanced glycosylation end products with cellular components within diabetic tissues.

Receptor-specific induction of insulin-like growth factor I in human monocytes by advanced glycosylation end product-modified proteins.

Regulation of mesangial cell growth by polypeptide mitogens. Inhibitory role of transforming growth factor beta.

P304

9436-9440

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1073/PNAS.91.20.9436

http://www.w3.org/2001/XMLSchema#string

P407

P433

20

http://www.w3.org/2001/XMLSchema#string

P478

91

http://www.w3.org/2001/XMLSchema#string

P577

1994-09-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

15261022

http://www.w3.org/2001/XMLSchema#string

P698

7937785

http://www.w3.org/2001/XMLSchema#string

P932

44827

http://www.w3.org/2001/XMLSchema#string